APO Research
Talk to an analyst

APO RESEARCH · REPORT

Circulating Tumor Cell(CTC)Detection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Circulating Tumor Cell(CTC)Detection Market Outlook and Growth Opportunities 2026

5 June 2026195 pages

Choose your research edition.

Industry ResearchCirculating Tumor Cell(CTC)Detection Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Circulating Tumor Cell(CTC)Detection Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Circulating Tumor Cell(CTC)Detection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Circulating Tumor Cell(CTC)Detection Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Circulating Tumor Cell(CTC)Detection Market Analysis and Forecast 2026-2032235 pages · $4,950 USD

Market perspective

The global Circulating Tumor Cell(CTC)Detection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Circulating Tumor Cell(CTC)Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Circulating Tumor Cell(CTC)Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Circulating Tumor Cell(CTC)Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Circulating Tumor Cell(CTC)Detection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Circulating Tumor Cell(CTC)Detection market include Rarecyte, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Fluxion Biosciences Inc., F. Hoffmann-La Roche AG, Sysmex Europe SE and Qiagen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Circulating Tumor Cell(CTC)Detection market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Circulating Tumor Cell(CTC)Detection and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Circulating Tumor Cell(CTC)Detection revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Circulating Tumor Cell(CTC)Detection market.

Circulating Tumor Cell(CTC)Detection Segment by Company

Rarecyte

ANGLE plc

Biocept Inc.

Bio-Rad Laboratories Inc.

Fluxion Biosciences Inc.

F. Hoffmann-La Roche AG

Sysmex Europe SE

Qiagen

Circulating Tumor Cell(CTC)Detection Segment by Type

Epithelial Cell Phenotype

Mesenchymal Cell Phenotype

Mixed Epithelial-Mesenchymal Phenotype

Circulating Tumor Cell(CTC)Detection Segment by Application

Cancer Diagnosis

Tumor Dynamic Assessment

Tumor Recurrence Monitoring

Circulating Tumor Cell(CTC)Detection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Circulating Tumor Cell(CTC)Detection status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Circulating Tumor Cell(CTC)Detection key companies, revenue, market share, and recent developments.

3. To split the Circulating Tumor Cell(CTC)Detection breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Circulating Tumor Cell(CTC)Detection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Circulating Tumor Cell(CTC)Detection significant trends, drivers, influence factors in global and regions.

6. To analyze Circulating Tumor Cell(CTC)Detection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cell(CTC)Detection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cell(CTC)Detection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cell(CTC)Detection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Circulating Tumor Cell(CTC)Detection industry.

Chapter 3: Detailed analysis of Circulating Tumor Cell(CTC)Detection company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Circulating Tumor Cell(CTC)Detection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Circulating Tumor Cell(CTC)Detection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Circulating Tumor Cell(CTC)Detection Industry Trends Table 2. Circulating Tumor Cell(CTC)Detection Industry Drivers Table 3. Circulating Tumor Cell(CTC)Detection Industry Opportunities and Challenges Table 4. Circulating Tumor Cell(CTC)Detection Industry Restraints Table 5. Global Circulating Tumor Cell(CTC)Detection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Circulating Tumor Cell(CTC)Detection Revenue Share by Company (2021-2026) Table 7. Global Circulating Tumor Cell(CTC)Detection Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Circulating Tumor Cell(CTC)Detection Key Company Manufacturing Base & Headquarters Table 9. Global Circulating Tumor Cell(CTC)Detection Company, Product Type & Application Table 10. Global Circulating Tumor Cell(CTC)Detection Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Circulating Tumor Cell(CTC)Detection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Epithelial Cell Phenotype Table 15. Significant Companies of Mesenchymal Cell Phenotype Table 16. Significant Companies of Mixed Epithelial-Mesenchymal Phenotype Table 17. Global Circulating Tumor Cell(CTC)Detection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Circulating Tumor Cell(CTC)Detection Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Circulating Tumor Cell(CTC)Detection Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Type (2021-2026) Table 21. Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Cancer Diagnosis Table 23. Significant Companies of Tumor Dynamic Assessment Table 24. Significant Companies of Tumor Recurrence Monitoring Table 25. Global Circulating Tumor Cell(CTC)Detection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Circulating Tumor Cell(CTC)Detection Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Circulating Tumor Cell(CTC)Detection Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Application (2021-2026) Table 29. Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Application (2027-2032) Table 30. Global Circulating Tumor Cell(CTC)Detection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Circulating Tumor Cell(CTC)Detection Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Region (2021-2026) Table 33. Global Circulating Tumor Cell(CTC)Detection Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Region (2027-2032) Table 35. Global Circulating Tumor Cell(CTC)Detection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Circulating Tumor Cell(CTC)Detection Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Circulating Tumor Cell(CTC)Detection Sales Value Market Share by Country (2021-2026) Table 38. Global Circulating Tumor Cell(CTC)Detection Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Circulating Tumor Cell(CTC)Detection Sales Value Market Share by Country (2027-2032) Table 40. Rarecyte Company Information Table 41. Rarecyte Business Overview Table 42. Rarecyte Circulating Tumor Cell(CTC)Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Rarecyte Circulating Tumor Cell(CTC)Detection Product Portfolio Table 44. Rarecyte Recent Development Table 45. ANGLE plc Company Information Table 46. ANGLE plc Business Overview Table 47. ANGLE plc Circulating Tumor Cell(CTC)Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. ANGLE plc Circulating Tumor Cell(CTC)Detection Product Portfolio Table 49. ANGLE plc Recent Development Table 50. Biocept Inc. Company Information Table 51. Biocept Inc. Business Overview Table 52. Biocept Inc. Circulating Tumor Cell(CTC)Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Biocept Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio Table 54. Biocept Inc. Recent Development Table 55. Bio-Rad Laboratories Inc. Company Information Table 56. Bio-Rad Laboratories Inc. Business Overview Table 57. Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio Table 59. Bio-Rad Laboratories Inc. Recent Development Table 60. Fluxion Biosciences Inc. Company Information Table 61. Fluxion Biosciences Inc. Business Overview Table 62. Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio Table 64. Fluxion Biosciences Inc. Recent Development Table 65. F. Hoffmann-La Roche AG Company Information Table 66. F. Hoffmann-La Roche AG Business Overview Table 67. F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Product Portfolio Table 69. F. Hoffmann-La Roche AG Recent Development Table 70. Sysmex Europe SE Company Information Table 71. Sysmex Europe SE Business Overview Table 72. Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Product Portfolio Table 74. Sysmex Europe SE Recent Development Table 75. Qiagen Company Information Table 76. Qiagen Business Overview Table 77. Qiagen Circulating Tumor Cell(CTC)Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Qiagen Circulating Tumor Cell(CTC)Detection Product Portfolio Table 79. Qiagen Recent Development Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Circulating Tumor Cell(CTC)Detection Product Image Figure 2. Global Circulating Tumor Cell(CTC)Detection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Circulating Tumor Cell(CTC)Detection Market Size (2021-2032) & (US$ Million) Figure 4. Global Circulating Tumor Cell(CTC)Detection Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Epithelial Cell Phenotype Image Figure 8. Mesenchymal Cell Phenotype Image Figure 9. Mixed Epithelial-Mesenchymal Phenotype Image Figure 10. Global Circulating Tumor Cell(CTC)Detection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Circulating Tumor Cell(CTC)Detection Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Type (2021-2032) Figure 13. Cancer Diagnosis Image Figure 14. Tumor Dynamic Assessment Image Figure 15. Tumor Recurrence Monitoring Image Figure 16. Global Circulating Tumor Cell(CTC)Detection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Circulating Tumor Cell(CTC)Detection Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Application (2021-2032) Figure 19. Global Circulating Tumor Cell(CTC)Detection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032) & (US$ Million) Figure 22. North America Circulating Tumor Cell(CTC)Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Circulating Tumor Cell(CTC)Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Circulating Tumor Cell(CTC)Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032) & (US$ Million) Figure 28. South America Circulating Tumor Cell(CTC)Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Circulating Tumor Cell(CTC)Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Epithelial Cell Phenotype
  • Mesenchymal Cell Phenotype
  • Mixed Epithelial-Mesenchymal Phenotype
Applications
  • Cancer Diagnosis
  • Tumor Dynamic Assessment
  • Tumor Recurrence Monitoring
Companies covered
  • Rarecyte
  • ANGLE plc
  • Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • Fluxion Biosciences Inc.
  • F. Hoffmann-La Roche AG
  • Sysmex Europe SE
  • Qiagen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Circulating Tumor Cell(CTC)Detection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Circulating Tumor Cell(CTC)Detection Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Circulating Tumor Cell(CTC)Detection Market Dynamics
  1. 2.1 Circulating Tumor Cell(CTC)Detection Industry Trends
  2. 2.2 Circulating Tumor Cell(CTC)Detection Industry Drivers
  3. 2.3 Circulating Tumor Cell(CTC)Detection Industry Opportunities and Challenges
  4. 2.4 Circulating Tumor Cell(CTC)Detection Industry Restraints
3 Circulating Tumor Cell(CTC)Detection Market by Company
  1. 3.1 Global Circulating Tumor Cell(CTC)Detection Company Revenue Ranking in 2025
  2. 3.2 Global Circulating Tumor Cell(CTC)Detection Revenue by Company (2021-2026)
  3. 3.3 Global Circulating Tumor Cell(CTC)Detection Company Ranking (2024-2026)
  4. 3.4 Global Circulating Tumor Cell(CTC)Detection Company Manufacturing Base and Headquarters
  5. 3.5 Global Circulating Tumor Cell(CTC)Detection Company Product Type and Application
  6. 3.6 Global Circulating Tumor Cell(CTC)Detection Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Circulating Tumor Cell(CTC)Detection Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Circulating Tumor Cell(CTC)Detection Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Circulating Tumor Cell(CTC)Detection Market by Type
  1. 4.1 Circulating Tumor Cell(CTC)Detection Type Introduction
  2. 4.1.1 Epithelial Cell Phenotype
  3. 4.1.2 Mesenchymal Cell Phenotype
  4. 4.1.3 Mixed Epithelial-Mesenchymal Phenotype
  5. 4.2 Global Circulating Tumor Cell(CTC)Detection Sales Value by Type
  6. 4.2.1 Global Circulating Tumor Cell(CTC)Detection Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Circulating Tumor Cell(CTC)Detection Sales Value by Type (2021-2032)
  8. 4.2.3 Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Type (2021-2032)
5 Circulating Tumor Cell(CTC)Detection Market by Application
  1. 5.1 Circulating Tumor Cell(CTC)Detection Application Introduction
  2. 5.1.1 Cancer Diagnosis
  3. 5.1.2 Tumor Dynamic Assessment
  4. 5.1.3 Tumor Recurrence Monitoring
  5. 5.2 Global Circulating Tumor Cell(CTC)Detection Sales Value by Application
  6. 5.2.1 Global Circulating Tumor Cell(CTC)Detection Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Circulating Tumor Cell(CTC)Detection Sales Value by Application (2021-2032)
  8. 5.2.3 Global Circulating Tumor Cell(CTC)Detection Sales Value Share by Application (2021-2032)
6 Circulating Tumor Cell(CTC)Detection Regional Value Analysis
  1. 6.1 Global Circulating Tumor Cell(CTC)Detection Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Circulating Tumor Cell(CTC)Detection Sales Value by Region (2021-2032)
  3. 6.2.1 Global Circulating Tumor Cell(CTC)Detection Sales Value by Region: 2021-2026
  4. 6.2.2 Global Circulating Tumor Cell(CTC)Detection Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032)
  7. 6.3.2 North America Circulating Tumor Cell(CTC)Detection Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032)
  10. 6.4.2 Europe Circulating Tumor Cell(CTC)Detection Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Circulating Tumor Cell(CTC)Detection Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032)
  16. 6.6.2 South America Circulating Tumor Cell(CTC)Detection Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Circulating Tumor Cell(CTC)Detection Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Circulating Tumor Cell(CTC)Detection Sales Value Share by Country, 2025 VS 2032
7 Circulating Tumor Cell(CTC)Detection Country-level Value Analysis
  1. 7.1 Global Circulating Tumor Cell(CTC)Detection Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Circulating Tumor Cell(CTC)Detection Sales Value by Country (2021-2032)
  3. 7.2.1 Global Circulating Tumor Cell(CTC)Detection Sales Value by Country (2021-2026)
  4. 7.2.2 Global Circulating Tumor Cell(CTC)Detection Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Circulating Tumor Cell(CTC)Detection Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Circulating Tumor Cell(CTC)Detection Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Circulating Tumor Cell(CTC)Detection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Rarecyte
  2. 8.1.1 Rarecyte Company Information
  3. 8.1.2 Rarecyte Business Overview
  4. 8.1.3 Rarecyte Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Rarecyte Circulating Tumor Cell(CTC)Detection Product Portfolio
  6. 8.1.5 Rarecyte Recent Developments
  7. 8.2 ANGLE plc
  8. 8.2.1 ANGLE plc Company Information
  9. 8.2.2 ANGLE plc Business Overview
  10. 8.2.3 ANGLE plc Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ANGLE plc Circulating Tumor Cell(CTC)Detection Product Portfolio
  12. 8.2.5 ANGLE plc Recent Developments
  13. 8.3 Biocept Inc.
  14. 8.3.1 Biocept Inc. Company Information
  15. 8.3.2 Biocept Inc. Business Overview
  16. 8.3.3 Biocept Inc. Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biocept Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
  18. 8.3.5 Biocept Inc. Recent Developments
  19. 8.4 Bio-Rad Laboratories Inc.
  20. 8.4.1 Bio-Rad Laboratories Inc. Company Information
  21. 8.4.2 Bio-Rad Laboratories Inc. Business Overview
  22. 8.4.3 Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
  24. 8.4.5 Bio-Rad Laboratories Inc. Recent Developments
  25. 8.5 Fluxion Biosciences Inc.
  26. 8.5.1 Fluxion Biosciences Inc. Company Information
  27. 8.5.2 Fluxion Biosciences Inc. Business Overview
  28. 8.5.3 Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
  30. 8.5.5 Fluxion Biosciences Inc. Recent Developments
  31. 8.6 F. Hoffmann-La Roche AG
  32. 8.6.1 F. Hoffmann-La Roche AG Company Information
  33. 8.6.2 F. Hoffmann-La Roche AG Business Overview
  34. 8.6.3 F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  35. 8.6.4 F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Product Portfolio
  36. 8.6.5 F. Hoffmann-La Roche AG Recent Developments
  37. 8.7 Sysmex Europe SE
  38. 8.7.1 Sysmex Europe SE Company Information
  39. 8.7.2 Sysmex Europe SE Business Overview
  40. 8.7.3 Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Product Portfolio
  42. 8.7.5 Sysmex Europe SE Recent Developments
  43. 8.8 Qiagen
  44. 8.8.1 Qiagen Company Information
  45. 8.8.2 Qiagen Business Overview
  46. 8.8.3 Qiagen Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Qiagen Circulating Tumor Cell(CTC)Detection Product Portfolio
  48. 8.8.5 Qiagen Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst